Form 4: Moderna Director Paul Sagan Acquires 25,512 Stock Options
SEC Form 4 Filing
Director Paul Sagan acquired 25,512 stock options in Moderna, Inc. on April 30, 2025, according to a Form 4 filing.
Summary
- Paul Sagan, a director of Moderna, Inc., acquired 25,512 stock options on April 30, 2025.
- The exercise price of these options is $28.54.
- The options vest fully on the earlier of April 30, 2026, or Moderna's next Annual Meeting of Shareholders, contingent upon continued service.
- The options expire on April 30, 2035.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard insider transaction filing. The acquisition of options could be seen as a slightly positive signal, but it's not a major event.
Positives
- A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Insider transactions are closely monitored as they can provide insights into a company's prospects. Form 4 filings are a routine part of regulatory compliance for company insiders.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 04/30/2025 | Date of transaction: Paul Sagan acquired 25,512 stock options. |
| 04/30/2026 | Options vest fully on the earlier of this date or Moderna's next Annual Meeting of Shareholders, subject to continued service. |
| 04/30/2035 | Expiration date of the stock options. |
| 05/01/2025 | Date of filing. |
Keywords
Moderna, MRNA, stock options, Form 4, insider trading, Paul Sagan, director
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.